Medexus Pharmaceuticals Inc T.MDP

Ixinity replacement therapy

[Napcoo]

Cost per patient per year should be above $200k, while Gene therapy should be above $2mln, per person, one time cost, this is why MDP withdraw some sales for ixinity. Predicting 5% drop in sales, it could be more and faster. 

Pfizer e.g approved in Canada, how many market share for covid? They are going to do the same with its Gene therapy
Prophylaxis therapy requires several infusions per week, and the cost can range from $300,000 to $776,000 per year.

https://www.pfizer.ca/en/media-centre/health-canada-approves-pfizer-canadas-gene-therapy-in-hemophilia-b

[Napcoo]

How much they've spent on ixinity? A lot, https://hemophilianewstoday.com/news/in-potential-100m-deal-medexus-acquires-global-rights-to-ixinity-hemophilia-b-therapy/ Rasuvu facing competition, paid a lot Treosulfan agreement is not a small number, Will it up for challenge? Yes, the generic drug, busulfan, manufactured by medac, before When you have only a fewand all  eggs in a

[Napcoo]

FDA-approved gene therapies In November 2022, the Food and Drug Administration approved Hemgenix, CSL Behring's hemophilia B gene therapy. Researchers at Children’s Hospital of Philadelphia are working on other types of gene therapies for hemophilia B with the goal of advancing treatment options for hemophilia B.

[Napcoo]

Gene therapy needs time to verify the long term results, giving replacement therapy such as ixinity a break https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b